Pfizer's Torisel misses endpoint in second kidney cancer trial this year
22:20 EDT 12 Aug 2012 | SCRIP
Pfizer posted its second set of topline results this year for a failed clinical trial seeking to expand the approved label for the oncology drug Torisel (temsirolimus) in renal cell carcinoma (RCC), this time in combination with Roche/Genentech's.....
Original Article: Pfizer's Torisel misses endpoint in second kidney cancer trial this year
More From BioPortfolio on "Pfizer's Torisel misses endpoint in second kidney cancer trial this year"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
